[
  {
    "ts": null,
    "headline": "Stock Market Today, Dec. 16: Pfizer Falls After Cutting 2025 Revenue Forecast",
    "summary": "Today, Dec. 16, 2025, Pfizer's shrinking COVID cash flows could mean little growth next year as M&A bets will take time to deliver.",
    "url": "https://finnhub.io/api/news?id=c9796abd71cdb84504ea07bde9c430766b017d06e13c0c8755cc60745cfbb2e8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765926221,
      "headline": "Stock Market Today, Dec. 16: Pfizer Falls After Cutting 2025 Revenue Forecast",
      "id": 137806038,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Today, Dec. 16, 2025, Pfizer's shrinking COVID cash flows could mean little growth next year as M&A bets will take time to deliver.",
      "url": "https://finnhub.io/api/news?id=c9796abd71cdb84504ea07bde9c430766b017d06e13c0c8755cc60745cfbb2e8"
    }
  },
  {
    "ts": null,
    "headline": "Stocks give up gain, Nasdaq drops led by Oracle: Live updates",
    "summary": "The S&P 500 and the Dow Industrials each booked a third consecutive losing session on Tuesday.",
    "url": "https://finnhub.io/api/news?id=f0faf42cebaf4dfa3c7b9de88672f9540dad03d4136332d143e65d9a8d6be474",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765908268,
      "headline": "Stocks give up gain, Nasdaq drops led by Oracle: Live updates",
      "id": 137812219,
      "image": "https://image.cnbcfm.com/api/v1/image/108228366-17635699152025-11-19t162534z_731137566_rc2pzhamtgbu_rtrmadp_0_usa-stocks.jpeg?v=1765986357&w=1920&h=1080",
      "related": "JNJ",
      "source": "CNBC",
      "summary": "The S&P 500 and the Dow Industrials each booked a third consecutive losing session on Tuesday. ",
      "url": "https://finnhub.io/api/news?id=f0faf42cebaf4dfa3c7b9de88672f9540dad03d4136332d143e65d9a8d6be474"
    }
  },
  {
    "ts": null,
    "headline": "Pharma M&A deal value up 31% YoY in 2025YTD amid return of mega-deals",
    "summary": "Large M&A transactions and bidding wars for Metsera and Avadel announced in H2 2025 reflect a need for large pharma companies to replenish pipelines through M&A ahead of looming patent cliffs.",
    "url": "https://finnhub.io/api/news?id=88e1f2697af7376f8d72c454a340650825068bf11ea9693bf371bc1d064e3e69",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765908089,
      "headline": "Pharma M&A deal value up 31% YoY in 2025YTD amid return of mega-deals",
      "id": 137806039,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Large M&A transactions and bidding wars for Metsera and Avadel announced in H2 2025 reflect a need for large pharma companies to replenish pipelines through M&A ahead of looming patent cliffs.",
      "url": "https://finnhub.io/api/news?id=88e1f2697af7376f8d72c454a340650825068bf11ea9693bf371bc1d064e3e69"
    }
  },
  {
    "ts": null,
    "headline": "3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most",
    "summary": "Healthcare behemoths, including the biggest name of them all, are increasing their dividends. Additionally, AMGN's dividend yield now sits solidly above 3%.",
    "url": "https://finnhub.io/api/news?id=9cd8737da98198d4adb0874e5e3ba292854fd719e179fe9cc6fa12f9c11a0030",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765894620,
      "headline": "3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most",
      "id": 137816785,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Healthcare behemoths, including the biggest name of them all, are increasing their dividends. Additionally, AMGN's dividend yield now sits solidly above 3%.",
      "url": "https://finnhub.io/api/news?id=9cd8737da98198d4adb0874e5e3ba292854fd719e179fe9cc6fa12f9c11a0030"
    }
  },
  {
    "ts": null,
    "headline": "2 Recession-Proof Stocks to Watch in December",
    "summary": "These companies have stood the test of time and survived many previous recessions.",
    "url": "https://finnhub.io/api/news?id=67eea11cc4aafa5302b5f7ec3791d9d5342759837b742037f480aefc8086f355",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765891500,
      "headline": "2 Recession-Proof Stocks to Watch in December",
      "id": 137806040,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "These companies have stood the test of time and survived many previous recessions.",
      "url": "https://finnhub.io/api/news?id=67eea11cc4aafa5302b5f7ec3791d9d5342759837b742037f480aefc8086f355"
    }
  },
  {
    "ts": null,
    "headline": "S&P Global Adds Hubert Joly to its Board of Directors",
    "summary": "S&P Global (NYSE: SPGI) announced today that its Board of Directors has approved the addition of Mr. Hubert Joly to the Board, effective January 2, 2026.",
    "url": "https://finnhub.io/api/news?id=325c79117193155e4fa1c7956d1990b6ffab7583a6206244b29f07cf8672b563",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765890300,
      "headline": "S&P Global Adds Hubert Joly to its Board of Directors",
      "id": 137806041,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "S&P Global (NYSE: SPGI) announced today that its Board of Directors has approved the addition of Mr. Hubert Joly to the Board, effective January 2, 2026.",
      "url": "https://finnhub.io/api/news?id=325c79117193155e4fa1c7956d1990b6ffab7583a6206244b29f07cf8672b563"
    }
  },
  {
    "ts": null,
    "headline": "Cradle AI-powered protein engineering platform serving six of top 25 pharma leaders",
    "summary": "Cradle, an enterprise-grade AI software platform, today announced a series of milestones that signal a new phase of growth. The company saw rapid adoption across the pharma industry, with Cradle now running 50+ projects and powering drug discovery programs for six of the top 25 big pharma companies, including Johnson & Johnson, Abbvie, and Novo Nordisk. To continue expanding product capabilities and meet surging global demand, the company has doubled headcount across all departments and expanded",
    "url": "https://finnhub.io/api/news?id=11ac9fc5d4be06d9c08abf1ee99c77e2dd30c8183a6de046f349850410397782",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765890000,
      "headline": "Cradle AI-powered protein engineering platform serving six of top 25 pharma leaders",
      "id": 137806042,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Cradle, an enterprise-grade AI software platform, today announced a series of milestones that signal a new phase of growth. The company saw rapid adoption across the pharma industry, with Cradle now running 50+ projects and powering drug discovery programs for six of the top 25 big pharma companies, including Johnson & Johnson, Abbvie, and Novo Nordisk. To continue expanding product capabilities and meet surging global demand, the company has doubled headcount across all departments and expanded",
      "url": "https://finnhub.io/api/news?id=11ac9fc5d4be06d9c08abf1ee99c77e2dd30c8183a6de046f349850410397782"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Adds to Its Big Bet on Weight Loss Drugs",
    "summary": "A month after acquiring obesity biotech Metsera, Pfizer's expanding in the weight loss drug market after signing a licensing agreement for a weight loss pill.",
    "url": "https://finnhub.io/api/news?id=0bf50c3ab54a5bdda61d0957c5bf307e8eb784f93f7a05e00a85977e902c81da",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765886580,
      "headline": "Pfizer Adds to Its Big Bet on Weight Loss Drugs",
      "id": 137816786,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "A month after acquiring obesity biotech Metsera, Pfizer's expanding in the weight loss drug market after signing a licensing agreement for a weight loss pill.",
      "url": "https://finnhub.io/api/news?id=0bf50c3ab54a5bdda61d0957c5bf307e8eb784f93f7a05e00a85977e902c81da"
    }
  },
  {
    "ts": null,
    "headline": "J&J Snack Foods to close 3 manufacturing sites in business revamp",
    "summary": "The Icee maker expects to accrue $20 million in annualized savings from a business transformation plan aimed at simplifying production and optimizing distribution.",
    "url": "https://finnhub.io/api/news?id=ede63fd768f98860cd58f63a07b38bebc25ab2c9e0803b660ae014db207e7184",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765881510,
      "headline": "J&J Snack Foods to close 3 manufacturing sites in business revamp",
      "id": 137806043,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The Icee maker expects to accrue $20 million in annualized savings from a business transformation plan aimed at simplifying production and optimizing distribution.",
      "url": "https://finnhub.io/api/news?id=ede63fd768f98860cd58f63a07b38bebc25ab2c9e0803b660ae014db207e7184"
    }
  },
  {
    "ts": null,
    "headline": "FDA ‘proactively’ hands J&J a voucher; Pfizer issues 2026 forecasts",
    "summary": "The FDA contacted J&J right after ASH to discuss using a special fast pass on a multiple myeloma regimen. Elsewhere, a new cell therapy player emerged and Sanofi cut deals with two startups.",
    "url": "https://finnhub.io/api/news?id=44a5c05615b5b31406cf0b8b992e99b544705e0613c769fed6df5ae261ae067f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765880400,
      "headline": "FDA ‘proactively’ hands J&J a voucher; Pfizer issues 2026 forecasts",
      "id": 137806044,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The FDA contacted J&J right after ASH to discuss using a special fast pass on a multiple myeloma regimen. Elsewhere, a new cell therapy player emerged and Sanofi cut deals with two startups.",
      "url": "https://finnhub.io/api/news?id=44a5c05615b5b31406cf0b8b992e99b544705e0613c769fed6df5ae261ae067f"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson: Quality Compounding, Valuations Now Do The Heavy Lifting",
    "summary": "Johnson & Johnson's organic growth and margin expansion remain moderate. Read why I would not add fresh capital to JNJ stock for now.",
    "url": "https://finnhub.io/api/news?id=d396429d2cc8f741a3eeed28320f1bc82fe3d3915d0e142f2164efc0b27b3fca",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765857250,
      "headline": "Johnson & Johnson: Quality Compounding, Valuations Now Do The Heavy Lifting",
      "id": 137800212,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1180491673/image_1180491673.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Johnson & Johnson's organic growth and margin expansion remain moderate. Read why I would not add fresh capital to JNJ stock for now.",
      "url": "https://finnhub.io/api/news?id=d396429d2cc8f741a3eeed28320f1bc82fe3d3915d0e142f2164efc0b27b3fca"
    }
  }
]